PEPLIN PHARMACEUTICALS FOR LIFE
DEAD

Serial Number

78484582

Owner

PEPLIN LIMITED

Attorney

James F. Harrington

Filing Date

Sep 16, 2004

Add to watchlist:

No watchlists yet
View on USPTO

PEPLIN PHARMACEUTICALS FOR LIFE Trademark

Serial Number: 78484582 • Registration: 3235825

PEPLIN PHARMACEUTICALS FOR LIFE is a trademark filed by PEPLIN LIMITED on September 16, 2004. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

PEPLIN LIMITED

LEVEL 2, BRISBANE PORTAL, 1 BREAKFAST
NEWSTEAD, QUEENSLAND 4006 , AU

Entity Type: 03

Peplin Biotech Ltd

Level 2, Brisbane Portal, 1 Breakfast Cr
Newstead, Queensland 4006 , AU

Entity Type: 03

Trademark Details

Filing Date

September 16, 2004

Registration Date

May 1, 2007

Published for Opposition

February 13, 2007

Cancellation Date

December 6, 2013

Goods & Services

Vaccines, pharmaceuticals, medical preparations, diagnostic preparations and therapeutic agents for the treatment, prevention and diagnosis of diabetes, dermatological, respiratory and/or inflammatory conditions, namely, acne, angina, arthritis, aspiration pneumonia, emphysema, gastroenteritis, intestinal flu, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy; Vaccines, pharmaceuticals, medical preparations, diagnostic preparations and therapeutic agents for the treatment of cancers, namely, tumors, sarcomas, carcinomas and melanomas including tumors of the colon, breast, neck, throat, bladder, brain, liver, pancreas, adrenal glands, lymph, testicles, uterus, ovaries, lung as well solid and blood borne tumors such as ABL1 protooncogene, AIDS related cancers, acoustic neuroma, acute lymphocyte leukemia, acute myeloid leukemia,adenocystic carcinoma, adrenocrtical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angio-sarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma, bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma-protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, fallopian tube cancer, fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, hematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's-cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer, ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, rare-cancers-and-associated-disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer of the bladder, transitional-cell-cancer of the renal, pelvis and ureter, trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's-macroglobulinemia and Wilms' tumor

Research and development, in relation to medical, biological and/or chemical diagnostic preparations, namely the identification evaluation and development of pharmaceuticals, pharmaceuticals for the treatment, prevention and diagnosis of diabetes, dermatological, respiratory and/or inflammatory conditions, namely, acne, angina, arthritis, aspiration pneumonia, emphysema, gastroenteritis, intestinal flu, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy; Research and development in relation to cancers including tumors, sarcomas, carcinomas and melanomas including tumors of the colon, breast, neck, throat, bladder, brain, liver, pancreas, adrenal glands, lymph, testicles, uterus, ovaries, lung as well solid and blood borne tumors such as ABL1 protooncogene, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angiosarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma, bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma-protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, fallopian tube cancer, fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, hematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's-cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer, ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, rare-cancers-and-associated-disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer of the bladder, transitional-cell-cancer of the renal, pelvis, ureter, trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's-macroglobulinemia and Wilms' tumor

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 6, 2013 C8..
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 5, 2013 TCCA
AMENDMENT UNDER SECTION 7 - PROCESSED
Aug 1, 2007 A7OK
ASSIGNED TO PARALEGAL
Jul 12, 2007 PLGL
SEC 7 REQUEST FILED
Jun 7, 2007 AMD7
PAPER RECEIVED
Jun 7, 2007 MAIL
REGISTERED-PRINCIPAL REGISTER
May 1, 2007 R.PR
PUBLISHED FOR OPPOSITION
Feb 13, 2007 PUBO
NOTICE OF PUBLICATION
Jan 24, 2007 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 15, 2006 PREV
ASSIGNED TO LIE
Dec 14, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 29, 2006 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 8, 2006 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 2, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 2, 2006 TROA
NON-FINAL ACTION MAILED
May 5, 2006 CNRT
NON-FINAL ACTION WRITTEN
May 5, 2006 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 6, 2006 TEME
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 5, 2006 ASGN
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 31, 2006 TROA
AMENDMENT FROM APPLICANT ENTERED
Feb 10, 2006 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 27, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 27, 2006 TROA
LETTER OF SUSPENSION MAILED
Nov 23, 2005 CNSL
SUSPENSION LETTER WRITTEN
Nov 23, 2005 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 1, 2005 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 26, 2005 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 26, 2005 TROA
NON-FINAL ACTION MAILED
Apr 27, 2005 CNRT
NON-FINAL ACTION WRITTEN
Apr 27, 2005 CNRT
ASSIGNED TO EXAMINER
Apr 17, 2005 DOCK
NEW APPLICATION ENTERED
Sep 22, 2004 NWAP